A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing elective primary total knee arthroplasty, open-label to treatment and observer-blinded to BAY 1213790 doses
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs BAY 1213790 (Primary) ; Apixaban; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Acronyms FOXTROT
- Sponsors Bayer
- 16 Jul 2018 Planned End Date changed from 14 Jun 2019 to 27 Mar 2019.
- 16 Jul 2018 Planned primary completion date changed from 27 Jan 2019 to 10 Nov 2018.
- 29 Jun 2018 This trial has been completed in Germany (end date: 2018-06-05)